Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opinion

Sort by: Newest first Oldest first A-Z Z-A

  • Sustiva oral solution discontinuation Subscription

    Bristol-Myers Squibb is discontinuing Sustiva (efavirenz) 30 mg/ml oral solution in the UK and Ireland on 31 October 2015. As a result of the Sustiva oral solution discontinuation, the paediatric indication for the Sustiva hard capsules and film coated tablets has been extended to include children from three months of age who weigh at least 3.5kg.

  • Speeding up the time it takes to register drugs, vaccines and diagnostics in low and middle income countries is a key strategy for the Bill and Melinda Gates Foundation. In the image, the headquarters of the foundation

    Gates Foundation aims to cut drug registration times by 50% in sub-Saharan Africa by 2018 Subscription

    Speeding up the time it takes to register drugs, vaccines and diagnostics in low and middle income countries is a key strategy for the Bill and Melinda Gates Foundation.

  • Videx warning Subscription

    The summary of product characteristics for Videx (didanosine; Bristol-Myers Squibb) now warns that while effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission of HIV, a residual risk cannot be excluded. It recommends precautions to prevent transmission should be taken in accordance with national guidelines.

  • Use of Incivo for HCV/HIV-1 co-infected patients

    The summary of product characteristics for Incivo (telaprevir; Janssen-Cilag) now states that HCV/HIV‑1 co‑infected patients should be treated in the same way as HCV mono‑infected patients. Drug interactions need to be carefully taken into account. Further changes to the SPC reflect this addition.

  • Rezolsta available for HIV Subscription

    Rezolsta, a darunavir 800mg and cobicistat 150mg combination tablet, is now available from Janssen for the treatment of HIV in adults. NHS list price, 30 tablets, £317.24. 

  • Time to fast-track the fight against HIV Subscription

    There are considerable challenges to address if global HIV/AIDS aspirations are to be accelerated.

  • Aids ‘family tree’ traced back to Kinshasa

    New research has traced the origin of the Aids pandemic back to 1920s Kinshasha, where a “perfect storm” of rapid population growth, a roaring sex trade, and good railway transport facilitated the spread of the HIV virus.

  • Andy Gray of the University of Kwazulu-Natal in Durban, South Africa, spoke on the shortage of retrovirals and consequences for patients

    Supply shortages of antiretrovirals can have devastating consequences for patients Subscription

    Medication non-adherence is not always within the patient’s control. Poor supply chain management and natural or other disasters can threaten access as well.

  • Dolutegravir approved in Wales Subscription

    Dolutegravir, in combination with other antiretrovirals, has been approved for use in NHS Wales by the All Wales Medicines Strategy Group to treat HIV infection in those aged 12 years and over.

  • Eviplera shelf life extended Subscription

    The shelf life of Eviplera (emtricitabine/rilpivirine/ tenofovir disoproxil) has been extended from two years to three years in the summary of product characteristics.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.